Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > James Telfser's Top Pick Tonite on Market Call
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(7)
•••
Comment by wordlesson Feb 23, 2016 9:55pm
276 Views
Post# 24587751

RE:RE:RE:James Telfser's Top Pick Tonite on Market Call

RE:RE:RE:James Telfser's Top Pick Tonite on Market Call
https://www.stockchase.com/company/find
 
 
  CXR-T   2016-02-23 TOP PICK James Telfser A rollup strategy that went bad. There have been so many pieces of negative news that have gone out on the pharmaceutical world, that they are missing the point of why this company made their last acquisition. It allowed them to dodge a bullet by getting out of North America and becoming more global. Trading at 4X earnings is basically saying that the company is going out of business, but next year they are going to generate $500 million in free cash flow, and will be able to de-lever pretty quickly. This is a business that can support a high debt load. Dividend yield of 1.09%.
   / Be the first to comment
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities